Shares of enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.20 and traded as high as $0.2749. enGene shares last traded at $0.26, with a volume of 1,505 shares trading hands.
enGene Stock Up 69.2%
The stock’s fifty day simple moving average is $0.20 and its 200-day simple moving average is $1.07.
About enGene
enGene is a clinical-stage biotechnology company developing non-viral gene therapies. Its approach is designed to deliver genetic material to targeted cells without using a viral vector. The company’s lead candidate, detalimogene voraplasmid (EG-70), is an investigational therapy administered directly into the bladder. It is being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment, and is intended to stimulate an immune response against cancer cells.
See Also
- Five stocks we like better than enGene
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
